MicroPort® Coronary Balloon Dilatation Catheter (Firefighter™ NC) Receives Registration Approval in Taiwan

Taiwan, China, 27 January 2021 - Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) has recently received a medical device license from the Taiwan Ministry of Health and Welfare (MOHW) for its proprietary coronary balloon dilatation catheter, Firefighter™ NC.

Firefighter™ NC is a new generation of high-pressure resistant and rapid exchange balloon dilatation catheters developed by MicroPort®, that follow its predecessor, Foxtrot™ NC. It is designed for balloon dilatation of stenoses in coronary tracts or coronary bypass bridges to improve myocardial perfusion. It is also used in post-balloon dilatation of stents after their implantation.

The outer surface of the catheter is coated with a hydrophilic polymer from the front and rear attachment points to the distal end of the product, which reduces friction on the surface of the catheter when combined with water during a surgery, thereby facilitating catheter’s delivery into and across lesions.

The market approval of Firefighter™ NC further broadens the coronary product portfolio of MicroPort® in Taiwan, China. As the Firehawk® Rapamycin Target Eluting Coronary Stent System, Firefighter™, and the Coronary Balloon Dilatation Catheter (Firefighter™ NC) successively enter the Taiwan market, MicroPort® is gaining influence and market share in the local market. In the future, MicroPort® will continue to expand the Taiwan market and provide local patients and doctors with high quality, universally accessible medical products and services.

If possible, consider attributing this sentence to a MicroPort spokesperson.